Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease
Open Access
- 25 February 2009
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 458 (7241) , 1039-1042
Abstract
The severity of lung disease in patients with cystic fibrosis varies markedly between individuals, and has been shown to have considerable heritability, independent of the genotype of the CFTR (cystic fibrosis transmembrane regulator) mutation that causes the primary disease. Genomic analysis of more than 300 cystic fibrosis patients has led to the identification of the neutrophil transcriptional co-regulator IFRD1 as a genetic modifier for lung disease, acting via an effect on neutrophil effectors. This finding highlights IFRD1 as a possible drug target in cystic fibrosis, of potential clinical significance because lung disease is the major cause of morbidity and mortality in the condition. Cystic fibrosis is more severe in some individuals than in others. This study identifies the neutrophil transcriptional co-regulator IFRD1 as a new genetic modifier. Lung disease is the major cause of morbidity and mortality in cystic fibrosis, an autosomal recessive disease caused by mutations in CFTR. In cystic fibrosis, chronic infection and dysregulated neutrophilic inflammation lead to progressive airway destruction. The severity of cystic fibrosis lung disease has considerable heritability, independent of CFTR genotype1. To identify genetic modifiers, here we performed a genome-wide single nucleotide polymorphism scan in one cohort of cystic fibrosis patients, replicating top candidates in an independent cohort. This approach identified IFRD1 as a modifier of cystic fibrosis lung disease severity. IFRD1 is a histone-deacetylase-dependent transcriptional co-regulator expressed during terminal neutrophil differentiation. Neutrophils, but not macrophages, from Ifrd1-deficient mice showed blunted effector function, associated with decreased NF-κB p65 transactivation. In vivo, IFRD1 deficiency caused delayed bacterial clearance from the airway, but also less inflammation and disease—a phenotype primarily dependent on haematopoietic cell expression, or lack of expression, of IFRD1. In humans, IFRD1 polymorphisms were significantly associated with variation in neutrophil effector function. These data indicate that IFRD1 modulates the pathogenesis of cystic fibrosis lung disease through the regulation of neutrophil effector function.Keywords
This publication has 32 references indexed in Scilit:
- Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airwayNature Immunology, 2004
- Regulation by C5a of Neutrophil Activation during SepsisImmunity, 2003
- The in vivo profile of transcription factors during neutrophil differentiation in human bone marrowBlood, 2003
- TIS7 interacts with the mammalian SIN3 histone deacetylase complex in epithelial cellsThe EMBO Journal, 2002
- Endotoxin Activity and Inflammatory Markers in the Airways of Young Patients with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Unbiased methods for population‐based association studiesGenetic Epidemiology, 2001
- Merlin—rapid analysis of dense genetic maps using sparse gene flow treesNature Genetics, 2001
- Natural Measles Causes Prolonged Suppression of Interleukin‐12 ProductionThe Journal of Infectious Diseases, 2001
- A General Test of Association for Quantitative Traits in Nuclear FamiliesThe American Journal of Human Genetics, 2000
- Development of an assay to measure in vivo cytokine production in the mouseInternational Immunology, 1999